Skip to main content
Log in

Primary hyperoxaluria type 1: still challenging!

  • Review
  • Published:
Pediatric Nephrology Aims and scope Submit manuscript

Abstract

Primary hyperoxaluria type 1, the most common form of primary hyperoxaluria, is an autosomal recessive disorder caused by a deficiency of the liver-specific enzyme alanine: glyoxylate aminotransferase (AGT). This results in increased synthesis and subsequent urinary excretion of the metabolic end product oxalate and the deposition of insoluble calcium oxalate in the kidney and urinary tract. As glomerular filtration rate (GFR) decreases due to progressive renal involvement, oxalate accumulates and results in systemic oxalosis. Diagnosis is still often delayed. It may be established on the basis of clinical and sonographic findings, urinary oxalate ± glycolate assessment, DNA analysis and, sometimes, direct AGT activity measurement in liver biopsy tissue. The initiation of conservative measures, based on hydration, citrate and/or phosphate, and pyridoxine, in responsive cases at an early stage to minimize oxalate crystal formation will help to maintain renal function in compliant subjects. Patients with established urolithiasis may benefit from extracorporeal shock-wave lithotripsy and/or JJ stent insertion. Correction of the enzyme defect by liver transplantation should be planned, before systemic oxalosis develops, to optimize outcomes and may be either sequential (biochemical benefit) or simultaneous (immunological benefit) liver–kidney transplantation, depending on facilities and access to cadaveric or living donors. Aggressive dialysis therapies are required to avoid progressive oxalate deposition in established end-stage renal disease (ESRD), and minimization of the time on dialysis will improve both the patient’s quality of life and survival.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Cochat P, Deloraine A, Rotily M, Olive F, Liponski I, Deries N, on behalf of the Société de Néphrologie and the Société de Néphrologie Pédiatrique (1995) Epidemiology of primary hyperoxaluria type 1. Nephrol Dial Transplant 10 [Suppl 8]:3–7

    PubMed  Google Scholar 

  2. Lieske JC, Monico CG, Holmes WS, Bergstralh EJ, Slezak JM, Rohlinger AL, Olson JB, Milliner DS (2005) International registry for primary hyperoxaluria. Am J Nephrol 25:290–296

    PubMed  Google Scholar 

  3. Al-Eisa AA, Samhan M, Naseef M (2004) End-stage renal disease in Kuwaiti children: an 8-year experience. Transplant Proc 36:1788–1791

    CAS  PubMed  Google Scholar 

  4. Kamoun A, Lakhoua R (1996) End-stage renal disease of the Tunisian child: epidemiology, etiologies and outcome. Pediatr Nephrol 10:479–482

    CAS  PubMed  Google Scholar 

  5. Cochat P, Koch Nogueira PC, Mahmoud AM, Jamieson NV, Scheinman JI, Rolland MO (1999) Primary hyperoxaluria in infants: medical, ethical and economic issues. J Pediatr 135:746–750

    CAS  PubMed  Google Scholar 

  6. Millan MT, Berquist WE, So SK, Sarwal MM, Wayman KI, Cox KL, Filler G, Salvatierra O Jr, Esquivel CO (2003) One hundred percent patient and kidney allograft survival with simultaneous liver and kidney transplantation in infants with primary hyperoxaluria: a single-center experience. Transplantation 76:1458–1463

    PubMed  Google Scholar 

  7. Cochat P, Rolland MO (2005) The primary hyperoxalurias. In: Davison AM, Cameron JS, Grünfeld JP, Ponticelli C, Ritz E, Winearls CG, van Ypersele C (eds) Oxford textbook of clinical nephrology (3rd edn). Oxford University Press, Oxford, pp 2374–2380

    Google Scholar 

  8. Danpure CJ (2005) Molecular etiology of primary hyperoxaluria type 1: new directions for treatment. Am J Nephrol 25:303–310

    PubMed  Google Scholar 

  9. Daudon M, Jungers P (2004) Clinical value of crystalluria and quantitative morphoconstitutional analysis of urinary calculi. Nephron Physiol 98:31–36

    Google Scholar 

  10. Wong PN, Law ELK, Tong GMW, Mak SK, Lo KY, Wong AKM (2003) Diagnosis of primary hyperoxaluria type 1 by determination of peritoneal dialysate glycolic acid using standard organic-acids analysis method. Perit Dial Int 23:S210–S213

    CAS  PubMed  Google Scholar 

  11. Coulter-Mackie MB, Rumsby G (2004) Genetic heterogeneity in primary hyperoxaluria type 1: impact on diagnosis. Mol Genet Metab 83:38–46

    CAS  PubMed  Google Scholar 

  12. Amoroso A, Pirulli D, Florian F, Puzzer D, Boniotto M, Crovella S, Zezlina S, Spano A, Mazzola G, Savoldi S, Ferrettini C, Berutti S, Petrarulo M (2001) AGXT gene mutations and their influence on clinical heterogeneity of type 1 primary hyperoxaluria. J Am Soc Nephrol 12:2072–2079

    CAS  PubMed  Google Scholar 

  13. Marangella M, Vitale C, Petrarulo M, Tricerri A, Cerelli E, Cadario A, Barbos MP, Linari F (1995) Bony content of oxalate in patients with primary hyperoxaluria or oxalosis-unrelated renal failure. Kidney Int 48:182–187

    CAS  PubMed  Google Scholar 

  14. Danpure CJ, Rumsby G (1995) Enzymological and molecular genetics of primary hyperoxaluria type 1. Consequences for clinical management. In: Khan SR (ed) Calcium oxalate in biological systems. CRC Press, Boca Raton, pp 189–205

    Google Scholar 

  15. Leumann E, Hoppe B (2005) Primary hyperoxaluria type 1: is genotyping clinically helpful? Pediatr Nephrol 20:555–557

    PubMed  Google Scholar 

  16. Coulter-Mackie MB, Applegarth D, Toone JR, Henderson H (2004) The major allele of the alanine:glyoxylate aminotransferase gene: seven novel mutations causing primary hyperoxaluria. Mol Genet Metab 82:64–68

    CAS  PubMed  Google Scholar 

  17. Danpure CJ (2004) Molecular aetiology of primary hyperoxaluria type 1. Nephron Exp Nephrol 98:e39–e44

    CAS  PubMed  Google Scholar 

  18. Lumb MJ, Danpure CJ (2000) Functional synergism between the most common polymorphism in human alanine:glyoxylate aminotransferase and four of the most common disease-causing mutations. J Biol Chem 275:36415–36422

    CAS  PubMed  Google Scholar 

  19. Monico CG, Persson M, Ford GC, Rumsby G, Milliner DS (2002) Potential mechanisms of marked hyperoxaluria not due to primary hyperoxaluria I or II. Kidney Int 62:392–400

    CAS  PubMed  Google Scholar 

  20. Nogueira PC, Vuong TS, Bouton O, Maillard A, Marchand M, Rolland MO, Cochat P, Bozon D (2000) Partial deletion of the AGXT gene (EX1_EX7del): a new genotype in hyperoxaluria type 1. Hum Mutat 15:384–385

    CAS  PubMed  Google Scholar 

  21. Rumsby G, Williams E, Coulter-Mackie M (2004) Evaluation of mutation screening as a first line test for the diagnosis of primary hyperoxaluria. Kidney Int 66:959–96323

    CAS  PubMed  Google Scholar 

  22. Basmaison O, Rolland MO, Cochat P, Bozon D (2000) Identification of 5 novel mutations in the AGXT gene. Hum Mutat 15:577

    CAS  PubMed  Google Scholar 

  23. van Woerden CS, Groothoff JW, Wijburg FA, Annink C, Wanders RJ, Waterham HR (2004) Clinical implications of mutation analysis in primary hyperoxaluria type 1. Kidney Int 66:746–752

    PubMed  Google Scholar 

  24. Monico CG, Rossetti S, Olson JB, Milliner DS (2005) Pyridoxine effect in type I primary hyperoxaluria is associated with the most common mutant allele. Kidney Int 67:1704–1709

    CAS  PubMed  Google Scholar 

  25. Coulter-Mackie MB (2005) Preliminary evidence for ethnic differences in primary hyperoxaluria type 1 genotype. Am J Nephrol 25:264–268

    PubMed  Google Scholar 

  26. von Schnakenburg C, Hulton SA, Milford DV, Roper HP, Rumsby G (1998) Variable presentation of primary hyperoxaluria type 1 in 2 patients homozygous for a novel combined deletion and insertion mutation in exon 8 of the AGXT gene. Nephron 78:485–488

    Google Scholar 

  27. Leumann E, Hoppe B (2001) The primary hyperoxalurias. J Am Soc Nephrol 12:1986–1993

    CAS  PubMed  Google Scholar 

  28. Milliner DS, Wilson DM, Smith LH (2001) Phenotypic expression of primary hyperoxaluria: comparative features of types I and II. Kidney Int 2001 59:31–36

    CAS  Google Scholar 

  29. Marangella M, Petrarulo M, Cosseddu D, Vitale C, Linari F (1992) Oxalate balance studies in patients on hemodialysis for type I primary hyperoxaluria. Am J Kidney Dis 19:546–553

    CAS  PubMed  Google Scholar 

  30. Hoppe B, Kemper MJ, Bokenkamp A, Portale A, Cohn R, Langman C (1999) Plasma calcium oxalate super saturation in children with primary hyperoxaluria and end-stage renal failure. Kidney Int 56:268–274

    CAS  PubMed  Google Scholar 

  31. Yamauchi T, Quillard M, Takahasi S, Nguyen-Khoa M (2001) Oxalate removal by daily dialysis in a patient with primary hyperoxaluria type 1. Nephrol Dial Transplant 16:2407–2411

    CAS  PubMed  Google Scholar 

  32. Scheinman JI, Najarian JS, Mauer SM (1984) Successful strategies for renal transplantation in primary oxalosis. Kidney Int 25:804–811

    CAS  PubMed  Google Scholar 

  33. Behnke B, Kemper MJ, Kruse HP, Müller-Wiefel DE (2001) Bone mineral density in children with primary hyperoxaluria type 1. Nephrol Dial Transplant 16:2236–2239

    CAS  PubMed  Google Scholar 

  34. Cibrik DM, Kaplan B, Arndorfer JA, Meier-Kriesche HU (2002) Renal allograft survival in patients with oxalosis. Transplantation 74:707–710

    CAS  PubMed  Google Scholar 

  35. Jamieson NV (2005) A 20-year experience of combined liver/kidney transplantation for primary hyperoxaluria (PH1): the European PH1 transplant registry experience 1984–2004. Am J Nephrol 25:282–289

    PubMed  Google Scholar 

  36. Cochat P, Schärer K (1993) Should liver transplantation be performed before advanced renal insufficiency in primary hyperoxaluria type 1? Pediatr Nephrol 7:212–218

    CAS  PubMed  Google Scholar 

  37. Kemper MJ (2005) The role of preemptive liver transplantation in primary hyperoxaluria type 1. Urol Res 33:376–379

    PubMed  Google Scholar 

  38. Gagnadoux MF, Lacaille F, Niaudet P, Revillon Y, Jouvet P, Jan D, Guest G, Charbit M, Broyer M (2001) Long term results of liver–kidney transplantation in children with primary hyperoxaluria. Pediatr Nephrol 16:946–950

    CAS  PubMed  Google Scholar 

  39. Ellis SR, Hulton SA, McKiernan PJ, de Ville de Goyet J, Kelly DA (2001) Combined liver–kidney transplantation for primary hyperoxaluria in young children. Nephrol Dial Transplant 16:348–354

    CAS  PubMed  Google Scholar 

  40. Sidhu H, Hoppe B, Hesse A, Tenbrock K, Bromme S, Rietschel E, Peck AB (1998) Absence of Oxalobacter formigenes in cystic fibrosis patients: a risk factor for hyperoxaluria. Lancet 352:1026–1029

    CAS  PubMed  Google Scholar 

  41. Chetyrkin SV, Kim D, Belmont JM, Scheinman JI, Hudson BG, Voziyan PA (2004) Pyridoxamine lowers kidney crystals in experimental hyperoxaluria: a potential therapy for primary hyperoxaluria. Kidney Int 67:53–60

    Google Scholar 

  42. Danpure CJ (2005) Primary hyperoxaluria: from gene defects to designer drugs? Nephrol Dial Transplant 20:1525–1529

    PubMed  Google Scholar 

  43. Koul S, Johnson T, Pramanik S, Koul H (2005) Cellular transfection to deliver alanine-glyoxylate aminotransferase to hepatocytes: a rational gene therapy for primary hyperoxaluria-1 (PH-1). Am J Nephrol 25:176–182

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Pierre Cochat.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cochat, P., Liutkus, A., Fargue, S. et al. Primary hyperoxaluria type 1: still challenging!. Pediatr Nephrol 21, 1075–1081 (2006). https://doi.org/10.1007/s00467-006-0124-4

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00467-006-0124-4

Keywords

Navigation